Avacta presents new comparisons of pre|CISION® payload release vs approved ADCs and AVA6207 dual payload delivery at Science Day 2026
Avacta Therapeutics (AIM: AVCT) Avacta data AACR underline AVA6103 profile
Avacta data at AACR 2026 underline favorable profile of AVA6103 and advantages of pre|CISION® delivery platform Presentation of additional analyses from FAP-Exd (AVA6103) study shows robust activity in PDX models with
Avacta Therapeutics (AIM: AVCT) Christina Coughlin – In Vivo 2026 Rising Leader
Avacta CEO Christina Coughlin Named as One of In Vivo’s 2026 Rising Leaders
Avacta Therapeutics (AIM: AVCT) Q1 2026 Business Update
LONDON and PHILADELPHIA – April 9, 2026 – Avacta Therapeutics (AIM: AVCT), a clinical stage biopharmaceutical company developing pre|CISION®, a tumor-activated oncology delivery platform, today provides a business update through the first
Avacta Therapeutics (AIM: AVCT) Announces 2026 Science Day Event
LONDON and PHILADELPHIA – April 8, 2026 – Avacta Therapeutics (AIM: AVCT), a clinical stage biopharmaceutical company developing pre|CISION®, a tumor-activated oncology delivery platform, is pleased to extend an open invitation for
Avacta Therapeutics (AIM: AVCT) First patient treated in Phase 1 trial of AVA6103
Avacta announces first patient treated in Phase 1 FOCUS-01 trial of FAP-Exd (AVA6103) – a sustained-release pre|CISION® exatecan peptide drug conjugate
Avacta raises £10m to fund next phase of cancer pipeline
Avacta Group has raised £10 million through an oversubscribed placing and subscription, issuing 15.87 million new shares at 63p, a discount of approximately 9.4% to the previous closing price.
Avacta Therapeutics (AIM: AVCT) Result of Oversubscribed Fundraise
Avacta Group plc has raised £10 million through an oversubscribed placing and subscription, highlighting strong investor demand.
Avacta to present new preclinical data on pre|CISION platform at AACR meeting
Avacta Group PLC has announced it will present new preclinical and translational data for its pre|CISION® platform at the 2026 American Association for Cancer Research (AACR) Annual Meeting, which will
Avacta Therapeutics (AIM: AVCT) Phase 1 study opening for AVA6103
Avacta announces opening of Phase 1 trial for second pipeline asset, FAP-Exd (AVA6103) a sustained-release pre|CISION® exatecan peptide-drug conjugate Specialty U.S. oncology centers open for recruitment in Virginia and Texas
Avacta Therapeutics (AIM: AVCT) PreCISION payload delivery advantage over ADC
Avacta’s pre|CISION Mechanism for Payload Delivery Shows Key Advantages Compared to an Antibody Drug Conjugate in Innovative AI-Driven Analysis
Avacta Therapeutics (AIM: AVCT) Appoints Francis Wilson as Chief Scientific Officer
Avacta Therapeutics (AIM: AVCT), a clinical stage biopharmaceutical company developing pre|CISION®, a tumor-activated oncology delivery platform, has appointed Francis Wilson as its Chief Scientific Officer.